Engineered Extracellular Vesicles for Stronger Vaccine Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing extracellular vesicles (EVs), such as exosomes, have limited clinical efficacy as drug delivery vehicles and immunotherapy agents, particularly in treating conditions like non-small cell lung cancer, due to insufficient immune response induction and limited therapeutic applications.
Innovation Solution
Engineered EVs comprising specific antigens and adjuvants, anchored or linked to scaffold moieties on the surface or within the vesicles, to enhance immune response induction, including CD4+ and CD8+ T cell responses, with optional immune modulators and targeting moieties for dendritic cells and T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional EVs (e.g., dendritic-cell derived exosomes) are used for immunotherapy, then they can be administered to patients, but they fail to induce sufficient immune response and achieve limited clinical efficacy
Solution Approach 1:
The patent combines multiple therapeutic components (antigens, adjuvants, and immune modulators) into a single engineered EV platform. This merging of previously separate therapeutic elements into one integrated delivery system enables synergistic immune activation, resolving the contradiction by making the EV sufficiently potent to induce strong immune responses while maintaining clinical applicability
Solution Approach 2:
The engineered EVs function as composite therapeutic materials containing multiple distinct components (antigens for specific immunity, adjuvants for immune activation, and modulators for response regulation). This composite structure allows the single EV platform to simultaneously address multiple aspects of immune response, achieving both high efficacy and sufficient immune activation
2Reliability
If EVs are engineered to carry multiple antigens and adjuvants, then immune response induction is enhanced, but the complexity of EV production and characterization increases
Solution Approach 1:
The patent creates a universal EV platform that can accommodate multiple different antigens, adjuvants, and immune modulators within the same vesicle structure. This multi-functional design allows a single production methodology to generate diverse therapeutic compositions, enhancing immune response capabilities while managing complexity through platform standardization
Solution Approach 2:
The patent systematically varies compositional parameters (types and amounts of antigens, adjuvants, and modulators) within the EV platform to optimize immune response. By treating the EV composition as adjustable parameters rather than fixed structures, the patent enhances therapeutic efficacy while maintaining production feasibility through parameter optimization rather than fundamental redesign
Data Source
AI summary
The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and/or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.